[EVENT] ISPOR Europe 2018

10-14 November 2018, Barcelona – Booth #501

ISPOR, the world’s leading organization for health economics & outcomes research, has invited Ipsos to present 18 posters at its forthcoming conference in Barcelona.

Our 18 posters – based on proprietary Real World Evidence and expertise in HEOR and Market Access – represent the combined strengths of Ipsos and our new colleagues, the former global healthcare team of GfK!
Please visit our newly extended team at Booth #501.

Below is a list of our poster sessions.  We look forward to seeing you in Barcelona.

PRESENTATION TITLE

SESSION

DATE

DISPLAY HOURS

RELATIVE VALUE ASSESSMENT OF TREATMENTS FOR RARE DISEASES

I

Monday, Nov 12, 2018

08:45 – 13:45

CLINICAL CHARACTERISTICS OF BIOLOGIC ELIGIBLE HIDRADENITIS SUPPURATIVA PATIENTS IN EU5

I

Monday, Nov 12, 2018

08:45 – 13:45

KILL/REPLACE/REGULATE: MOLECULAR-LEVEL VIEW OF TREATING DISEASE, EMERGING SOLUTIONS AND IMPLICATIONS FOR THE FUTURE OF HEALTHCARE

I

Monday, Nov 12, 2018

08:45 – 13:45

IS DIGITAL TECHNOLOGY BRINGING THE ADOPTERS CLOSER TO THE DECISION MAKERS? A COMPARATIVE ASSESSMENT ACROSS FIVE EUROPEAN MARKETS

I

Monday, Nov 12, 2018

08:45 – 13:45

GENE THERAPY CRISIS: HOW WILL THE CURRENT PIPELINE AFFECT THE PHARMACEUTICAL INDUSTRY AND HEALTHCARE SYSTEMS?

I

Monday, Nov 12, 2018

08:45 – 13:45

HOSPITALIZATION RATES AMONG EMERGENCY ROOM-DIAGNOSED HIV+ PATIENTS IN THE US AND EU5

II

Monday, Nov 12, 2018

15.45 – 19.15

DELAY BETWEEN HIV DIAGNOSIS AND TREATMENT INITIATION ACROSS THE EU5

II

Monday, Nov 12, 2018

15.45 – 19.15

CLINICAL CHARACTERISTICS OF BIOLOGIC TREATED CROHN’S DISEASE PATIENTS WITH AND WITHOUT PRIOR SURGERY IN EUROPEAN UNION

III

Tuesday, Nov 13, 2018

08:45 – 13:30

IDENTIFYING THE CHANGES REQUIRED IN HEALTH TECHNOLOGY ASSESSMENT SYSTEMS IF OUTCOMES ARE TO BE OPTIMIZED IN A DIGITAL WORLD WHERE PERSONALIZED DATA AND PRECISION MEDICINE COLLIDE

III

Tuesday, Nov 13, 2018

08:45 – 13:30

THE EFFECT OF EUNETHTA ASSESSMENTS ON NATIONAL HTA DECISION MAKING

III

Tuesday, Nov 13, 2018

08:45 – 13:30

IS THE EUROPEAN BIOSIMILARS MEDICINES MARKET BECOMING UNSUSTAINABLE? AN EXPLORATION OF THE COMBINED IMPACT OF COMPETITION, INTERCHANGEABILITY, PROCUREMENT AND PRICING

III

Tuesday, Nov 13, 2018

08:45 – 13:30

DIRECTIVE 2004/18/EC: IMPLICATIONS FOR PUBLIC MEDICINE PROCUREMENT IN EUROPE

III

Tuesday, Nov 13, 2018

08:45 – 13:45

COMPARATIVE ANALYSIS OF BIOSIMILAR RITUXIMAB USAGE IN TREATING NON-HODGKIN LYMPHOMA AND RHEUMATOID ARTHRITIS: RESULTS FROM A MULTI-COUNTRY STUDY IN EUROPE

III

Tuesday, Nov 13, 2018

08:45 – 13:30

30-DAY MORTALITY RATES FOLLOWING HOSPITAL ADMISSION FOR ULCERATIVE COLITIS AND CLOSTRIDIUM DIFFICILE INFECTION

III

Tuesday, Nov 13, 2018

08:45 – 13:30

COMPARATIVE ANALYSIS OF ESMO MAGNITUDE OF CLINICAL BENEFIT SCALE VALUES ASSIGNED TO NSCLC CANCER DRUGS, VERSUS REAL WORLD DATA ON PRESCRIBING ACTIVITY AND LEVELS OF SATISFACTION IN THE EU5

III

Tuesday, Nov 13 2018

08.45 – 13.15

DECREASED WORK PRODUCTIVITY AND INCREASED HEALTHCARE RESOURCE UTILISATION (HRU) AMONG PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) – RESULTS FROM A REAL WORLD EVIDENCE STUDY

III

Tuesday, Nov 13 2018

08.45 – 13.30

HUMANISTIC BURDEN OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) – IN THE FIRST REAL-WORLD CROSS-SECTIONAL STUDY, SYMPTOMATIC NASH PATIENTS REPORT WORSE QUALITY OF LIFE

III

Tuesday, Nov 13 2018

08.45 – 13.30

UTILIZING ADVANCED DATA ANALYSIS AND VISUALIZATION, POWERED BY ARTIFICIAL INTELLIGENCE, TO ANALYZE PRICE MIGRATION DATA FOR ONCOLOGY PRODUCTS

IV

Tuesday, Nov 13 2018

15:30-19:00

COMPARATIVE ANALYSIS OF PROFILES OF STAGE IIIB/IV NSCLC PATIENTS BY TIME FROM DIAGNOSIS TO FIRST TREATMENT IN WESTERN EUROPE

V

Wednesday, Nov 14, 2018

08.45 – 13.15

COMPARATIVE ANALYSIS OF PROFILES OF STAGE IIIB/IV NSCLC PATIENTS BY TIME FROM DIAGNOSIS TO FIRST TREATMENT IN THE UNITED STATES

V

Wednesday, Nov 14, 2018

08.45 – 13.15

Register here

View the program

More insights about Health

Society